Why Ligand Pharmaceuticals Stock Is Back on Investors’ Radar

Ligand Pharmaceuticals (LGND) is in focus after reporting second quarter 2026 results that showed higher revenue and net income compared with a year earlier, while management also reaffirmed full year revenue and earnings guidance.

The earnings release and reaffirmed 2026 guidance appear to have supported sentiment around Ligand Pharmaceuticals, with the stock posting a 41.71% 90 day share price return and a 94.99% 1 year total shareholder return from a much stronger multi year base.

If the Ligand story has you looking for other potential opportunities in healthcare, this could be a good moment to review 42 healthcare AI stocks

Bulls point to Ligand Pharmaceuticals’ sharp profit swing and guidance as support for the recent share price surge. Bears see too much optimism baked in already. Which side does the current valuation actually support next?

Most Popular Narrative: 8.9% Undervalued

The most followed narrative for Ligand Pharmaceuticals places fair value at $323.30, compared with the last close of $294.60, and ties that gap directly to royalty driven growth assumptions.

Strong revenue and earnings growth are expected as Ligand broadens its high margin royalty portfolio, with multiple partnered drugs (such as O2vir, Filspari, Qarziba, and Zelsuvmi) in various stages of commercialization or late stage development. This expanding royalty base enhances recurring revenue, earnings visibility, and long term cash flow predictability.

Want to see what sits behind that royalty growth story and the fair value uplift? The narrative leans on ambitious revenue expansion, firm margins and a premium earnings multiple that is usually reserved for faster growing sectors.

Result: Fair Value of $323.30 (UNDERVALUED)

However, you also need to factor in the risk that drug pricing pressure or underperformance from key royalty assets could quickly challenge the current Ligand Pharmaceuticals narrative.

Another View: What Ligand Pharmaceuticals’ P/E Says

The popular narrative has Ligand Pharmaceuticals looking about 8.9% undervalued on fair value of $323.30 versus a $294.60 share price. Yet the current P/E of 29.8x is far higher than the US Pharmaceuticals industry at 16.9x, the peer average at 18.2x, and a fair ratio of 22.6x.

That gap suggests the market is already paying a premium for Ligand Pharmaceuticals, so any slip in growth or royalties could matter more here than in a lower rated stock.

Next Steps

The debate around Ligand Pharmaceuticals is clearly split between optimism about royalties and concern about what could go wrong, so move quickly and test those claims against the numbers yourself. To see the full mix of potential upsides and flagged issues in one place, review the 3 key rewards and 1 important warning sign

Looking For More Investment Ideas Beyond Ligand Pharmaceuticals?

If the Ligand Pharmaceuticals story has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to compare fresh ideas across different styles.

• Target potential mispriced opportunities before the crowd notices by checking the 52 high quality undervalued stocks.
• Strengthen your defense with companies that prioritize balance sheets and cash flows through the solid balance sheet and fundamentals stocks screener (51 results).
• Hunt for underfollowed potential where fewer eyes are looking by using the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.